Edition:
United Kingdom

Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

6.08USD
14 Dec 2018
Change (% chg)

$0.01 (+0.16%)
Prev Close
$6.07
Open
$6.08
Day's High
$6.28
Day's Low
$6.00
Volume
3,252
Avg. Vol
12,330
52-wk High
$12.21
52-wk Low
$5.58

Summary

Name Age Since Current Position

Mark Goldsmith

56 2009 Independent Chairman of the Board

Jigar Raythatha

41 2017 President, Chief Executive Officer, Director

Emma Reeve

57 2017 Chief Financial Officer, Senior Vice President

Brenda Sousa

54 2017 Senior Vice President of Human Resources

Brad Prosek

2017 Senior Vice President, Corporate Development

Adrian Senderowicz

54 2017 Senior Vice President and Chief Medical Officer

Robert Sims

44 2017 Senior Vice President of Research

Patrick Trojer

45 2017 Senior Vice President, EZH2, Franchise and Head of Translational Sciences

James Audia

62 2017 Director

Anthony Evnin

77 2008 Independent Director

Steven Hoerter

47 2018 Independent Director

Peter Svennilson

56 2016 Independent Director

Robert Tepper

63 2008 Independent Director

Elizabeth Trehu

58 2018 Independent Director

Ronald Aldridge

2017 IR Contact Officer

Biographies

Name Description

Mark Goldsmith

Dr. Mark A. Goldsmith, M.D. Ph.D. is Independent Chairman of the Board of the company since July 2009. Dr. Goldsmith has been the president and chief executive officer and a director of Revolution Medicines, a drug discovery and development company, since November 2014. Dr. Goldsmith was previously a partner with Third Rock Ventures, L.P., or Third Rock, a venture capital firm, from March 2012 until 2015 and a venture partner with Third Rock from 2015 until March 2018. Dr. Goldsmith previously served as our president and chief executive officer from June 2009 to March 2012 and as our interim executive chairman from June 2016 to March 2017. Dr. Goldsmith served as president and chief executive officer of Global Blood Therapeutics, a biotechnology company, from May 2012 to June 2014, and on its board of directors from May 2012 to September 2014. Dr. Goldsmith also served as president and chief executive officer of Nurix, Inc., a drug discovery company, from May 2012 to October 2014. Dr. Goldsmith also serves on the board of directors of various private biotechnology companies. From 2006 to 2009, Dr. Goldsmith served as chief executive officer and chairman of Cogentus Pharmaceuticals, Inc., a biotechnology company, which filed a petition for bankruptcy under Chapter 7 of the United States Bankruptcy Code in 2009. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. Dr. Goldsmith holds an A.B. from Princeton University and a M.D. and Ph.D. in microbiology and immunology from the University of California, San Francisco.

Jigar Raythatha

Mr. Jigar Raythatha severs as President and Chief Executive Officer, Director of the company since March 2017. Mr. Raythatha previously served as chief business officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017, where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our head of corporate development from March 2009 to February 2013, where he led business development, strategy and program and alliance management functions. Prior to serving as our head of corporate development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman fellow from 2005 to 2007, principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University. We believe that Mr. Raythatha’s extensive leadership experience in the life sciences industry and his extensive knowledge of our company based on his prior role as our head of corporate development and in his current role as our chief executive officer qualify him to serve as a member of our board of directors.

Emma Reeve

Ms. Emma Reeve serves as Senior Vice President and Chief Financial Officer of the company since October 2017 and as our treasurer and secretary since December 2017. Prior to joining us, Ms. Reeve served as corporate controller of PAREXEL International, a life sciences consulting firm and contract research organization, from September 2014 to October 2017 and as interim chief financial officer and corporate controller of PAREXEL from July 2016 to May 2017, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve served as head of finance and administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014 and as vice president, global head business planning and analysis for Novartis Vaccines and Diagnostics, a division of Novartis, from January 2008 to April 2012. She served as chief financial officer of Inotek Pharmaceuticals Inc., a development-stage biotechnology company, from 2006 to 2007. Ms. Reeve was senior director of research operations at Merck Research Laboratories from 2004 to 2006. Prior to that she served as chief financial officer of Aton Pharma, Inc., a development-stage biotechnology company, from 2002 to 2004. Ms. Reeve was at Bristol-Myers Squibb Company, a global biopharmaceuticals company, from 1994 to 2002. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.

Brenda Sousa

Ms. Brenda Sousa is the senior vice president of human resources and operations since April 2017 and, before that, served as our vice president of human resources from March 2010 to April 2017. Prior to joining us, Ms. Sousa served in a number of roles of increasing responsibility at EPIX Pharmaceuticals, a pharmaceutical company, from 1998 to July 2009, including, most recently, as vice president, human resources and operations. Before joining EPIX, she was director of human resources for RKS Health Ventures and Spence Center for Women’s Health from 1995 to 1998. Ms. Sousa holds a B.A. from the University of Massachusetts, Lowell.

Brad Prosek

Mr. Brad Prosek serves as senior vice president, corporate development of the company since September 2017. Prior to joining us, Mr. Prosek was the president of All Terrain bioPartners LLC, a business development consulting firm, from April 2015 to September 2017, where he advised and supported life sciences companies, including us from June 2017 until the commencement of his employment with us. Before that, Mr. Prosek was employed in various roles at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from March 2005 to April 2015, including as senior director, corporate development from January 2009 to August 2014 and as head of infection and prevention technology and services from August 2014 to April 2015. Prior to Cubist, Mr. Prosek served in commercial operations and business development roles at Biogen Inc. from 1999 to 2005. Mr. Prosek holds an M.B.A. from Columbia University and a B.S.F.S. from Georgetown University in international relations.

Adrian Senderowicz

Dr. Adrian Senderowicz, M.D. serves as Senior Vice President and Chief Medical Officer of the company since July 2017, prior to which he provided consulting services to us from May 2017 until the commencement of his employment with us. Prior to joining us, Dr. Senderowicz served as chief medical officer at Cerulean Pharma, Inc., an oncology-focused biotechnology company now known as Daré Bioscience, Inc., from September 2015 to June 2017, where he helped secure Fast Track designation for the company’s lead clinical development program in two indications. Previously, Dr. Senderowicz was chief medical officer and senior vice president, clinical development and regulatory affairs at Ignyta, Inc., a biotechnology company, from August 2014 to April 2015. Prior to that he was vice president, global oncology regulatory head at Sanofi S.A., a global pharmaceutical company, from July 2013 to August 2014 and served as chief medical officer at Tokai Pharmaceuticals, Inc., a biopharmaceutical company now known as Novus Therapeutics, Inc., from August 2012 to March 2013. Dr. Senderowicz was a medical director and senior medical director at AstraZeneca PLC, a global biopharmaceutical company, from 2008 to 2012. He began his career as an investigator at the National Cancer Institute before joining the Center for Drug Evaluation and Research at the FDA. Since September 2015, Dr. Senderowicz has served on the board of directors of Puma Biotechnology, a public biotechnology company. Dr. Senderowicz is a board-certified medical oncologist. Dr. Senderowicz completed his Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai and a Clinical Oncology Fellowship at the National Cancer Institute. He holds an M.D. degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.

Robert Sims

Dr. Robert Sims, Ph.D. serves as Senior Vice President of Research of the company since June 2017. Dr. Sims joined us in 2008 as a founding scientist and has served in various scientific roles at our company, including as vice president, research from 2015 to June 2017, executive director, biology from 2014 to 2015, senior director, biology from 2012 to 2014, director, biology from 2010 to 2012, senior scientist from 2009 to 2010 and scientist from 2008 to 2009. He received his Ph.D. in cellular and molecular biology from the University of Texas at Austin and completed his postdoctoral training at the Robert Wood Johnson Medical School and the New York University School of Medicine.

Patrick Trojer

Mr. Patrick Trojer, Ph.D. serves as Senior Vice President, EZH2, Franchise and Head of Translational Sciences of the company since June 2017. Dr. Trojer joined as a founding scientist in 2008. Dr. Trojer has served in various positions at our company, including as vice president, head of research from October 2015 to June 2017, executive director, head of biology from October 2014 to October 2015, senior director, head of biology from March 2012 to October 2014, director, head of biology from 2010 to March 2012, senior scientist from 2009 to 2010 and scientist from 2008 to 2009. Dr. Trojer completed his postdoctoral studies at NYU Medical School, prior to which he received a Ph.D. in protein biochemistry and molecular biology and an M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.ince June 2017. Dr. Trojer joined as a founding scientist in 2008. Dr. Trojer has served in various positions at our company, including as vice president, head of research from October 2015 to June 2017, executive director, head of biology from October 2014 to October 2015, senior director, head of biology from March 2012 to October 2014, director, head of biology from 2010 to March 2012, senior scientist from 2009 to 2010 and scientist from 2008 to 2009. Dr. Trojer completed his postdoctoral studies at NYU Medical School, prior to which he received a Ph.D. in protein biochemistry and molecular biology and an M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.

James Audia

Dr. James E. Audia, Ph.D., serves as Director of the company since July 2017. Dr. Audia currently serves as Executive Director of the Chicago Biomedical Consortium, or CBC, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation. Prior to joining the CBC in August 2017, Dr. Audia served as our chief scientific officer from January 2011 to July 2017. Prior to joining us as chief scientific officer, Dr. Audia served in a number of roles at Eli Lilly & Company, a global healthcare company, from 1987 until December 2010. From January 2011 to December 2017, Dr. Audia served as a scientific advisor to Sage Therapeutics, Inc., a public biopharmaceutical company. Dr. Audia also serves as a scientific advisor and a member of the board of directors of Ribon Therapeutics, Inc., a private biotechnology company. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University.

Anthony Evnin

Mr. Anthony Evnin, Ph.D. serves as Independent Director of the company since April 2008. Dr. Evnin is a partner of Venrock, a venture capital firm, where he has been a partner since 1975. He currently serves on the boards of AVEO Pharmaceuticals, Inc. and Infinity Pharmaceuticals, Inc., each a public biopharmaceutical company, and Cantel Corporation, a public medical equipment company, as well as a number of private biopharmaceutical companies. During the last five years, Dr. Evnin has served as a director of Juno Therapeutics, Inc., Acceleron Pharma, Inc. and CymaBay Therapeutics, Inc. (formerly Metabolex, Inc.), each a public biopharmaceuticals company. Dr. Evnin is a trustee emeritus of The Rockefeller University, a trustee of The Jackson Laboratory, a trustee emeritus of Princeton University, and a member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Dr. Evnin holds a Ph.D. in chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University

Steven Hoerter

Mr. Steven L. Hoerter is Independent Director of the Company. He has served as the chief commercial officer of Agios Pharmaceuticals, a biopharmaceutical company, since February 2016. He has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served, from August 2011 to February 2016, as executive vice president and chief commercial officer at Clovis Oncology, Inc., a biopharmaceutical company. There, Mr. Hoerter built and led the global commercial organization that developed go-to-market strategies for two oncology therapies. Before joining Clovis in August 2011, he was general manager and management center head at Roche Group for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s bio-oncology business as senior director, pipeline development and commercial operations. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the United States, Europe and Africa. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University.

Peter Svennilson

Mr. Peter Svennilson serves as Independent Director of the company since June 2016. In February 2007, Mr. Svennilson founded The Column Group, a venture capital firm, as serves as its managing partner. He currently serves as a member of the board of directors of Immune Design Corp., a publicly-traded immunotherapy company, as well as a number of private biopharmaceutical companies. From 2010 to March 2013, Mr. Svennilson served as a director of PTC Therapeutics, Inc., a biopharmaceutical company. Prior to founding The Column Group, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. Prior to Three Crowns Capital, he was the associate managing director in charge of European Investment Banking Origination at Nomura Securities. Mr. Svennilson is currently a trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.

Robert Tepper

Dr. Robert Tepper, M.D. serves Independent Director of the company since April 2008. Dr. Tepper is a general partner of Third Rock, which he co-founded in March 2007 and focuses on the formation, development and scientific strategy of Third Rock’s portfolio companies, as well as actively identifying and evaluating new investments. Dr. Tepper served as our chief scientific officer from April 2008 to October 2009. Prior to joining Third Rock, Dr. Tepper served as President of Research and Development at Millennium Pharmaceuticals, Inc., or Millennium. Prior to joining Millennium in 1994, he served as principal investigator in the laboratory of tumor biology at the Massachusetts General Hospital Cancer Center. Dr. Tepper is also a founder and former member of the scientific advisory board of Cell Genesys/Abgenix Inc. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several healthcare institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Dr. Tepper serves a board member of Kala Pharmaceuticals Inc., Jounce Therapeutics, Inc. and Allena Pharmaceuticals, Inc., each a biopharmaceutical company, and was previously a board member of bluebird bio, Inc. from 2010 to 2015 and Cerulean Pharma Inc. from 2006 to 2015. Dr. Tepper is currently a board member of several private life sciences companies. Dr. Tepper also serves on the board of overseers at Tufts University and on the Council of the National Center for Advancing Translational Sciences at the National Institutes of Health. Dr. Tepper holds an A.B. in biochemistry from Princeton University and an M.D. from Harvard Medical School. We believe that Dr. Tepper’s experience in the venture capital industry, particularly with biotechnology and pharmaceutical companies,

Elizabeth Trehu

Dr. Elizabeth G. Trehu, M.D. is Independent Director of the Company. She has served as the chief medical officer of Jounce Therapeutics, Inc., a clinical stage immunotherapy company, since November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010, vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. From 2002 to 2006, Dr. Trehu served in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.

Ronald Aldridge